Drugs / MK-8521
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01982630 | Nov 2013 → Oct 2014 | diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02055547 | May → Sep 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02492763 | Jul 2015 → Apr 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02492763 ↗ |
| Route | Subcutaneous | “once daily subcutaneous MK-8521” NCT01982630 ↗ |